Skip to main content
Harvard Office of Technology Development logo

The Blavatnik Biomedical Accelerator Advisory Committee

The Blavatnik Biomedical Accelerator Advisory Committee comprises academic thought leaders and accomplished members of the biopharma and life-science venture communities. This distinguished group provides critical input on project selection and oversight, helping to ensure that research work plans have been designed to drive results, add value, and effectively address key criteria for licensing.

KEVIN BITTERMAN, PhD
Partner
Atlas Ventures

ALEXIS BORISY
Operating Chairman
Curie Bio
Executive Chairman, EQRx

ANGELIKA FRETZEN, PhD, MBA
Chief Operating Officer and Technology Translation Director
Wyss Institute at Harvard University

CHRISTINA ISACSON, PhD
Partner
Lightstone Ventures

ANTHONY MANNING, PhD
Principal at Manning Bio Worldwide LLC
Previously Chief Scientific Officer, Momenta Pharma

MARK NAMCHUK, PhD
Puja and Samir Kaul Professor of the Practice of Biomedical Innovation and Translation
Professor of the Practice of Biological Chemistry and Molecular Pharmacology
Executive Director of Therapeutics Translation at Harvard Medical School

DEB PALESTRANT, PhD, MBA
Partner, Head of 4:59
5AM Ventures

ARLENE SHARPE, PhD
George Fabyan Professor of Comparative Pathology, Chair of the Department of Immunology
Blavatnik Institute at Harvard Medical School

STEVE TREGAY, PhD
Managing Partner
Mission BioCapital

AMY WAGERS, PhD
Forst Family Professor of Stem Cell and Regenerative Biology, Chair of Harvard Department of Stem Cell and Regenerative Biology
Department of Stem Cell and Regenerative Biology

STACIE WENINGER, PhD
Venture Partner
F-Prime Capital